H B Fuller CompanyAnalyst price targets split and blended fair value trimmed to US$69.86 from US$73.29 on H.B. Fuller, with mixed Buy ratings and a Baird cut on execution risk.

H.B. Fuller's blended analyst fair value has been trimmed to US$69.86 from US$73.29 as price targets on the stock split between bulls and bears. Seaport Research keeps a Buy rating with a US$80 target, trimmed from US$84 to reflect risk tied to the proposed Advanced Medical Solutions acquisition, while Citi maintains a Buy rating and a US$75 target and Deutsche Bank keeps a Buy rating with a US$72 target. On the bearish side, Baird cut its target to US$65 from US$75, citing execution risk and the balance between growth and valuation. The revised models also lowered the revenue growth assumption to 6.38% from 7.27%, raised the net profit margin expectation to 5.93% from 5.73%, cut the future P/E to 18.66x from 19.88x, and lifted the discount rate to 8.53% from 8.32%.
H B Fuller CompanyAnalyst price targets split and blended fair value trimmed to US$69.86 from US$73.29 on H.B. Fuller, with mixed Buy ratings and a Baird cut on execution risk.
China Nonferrous Mining Corp Ltd
Advanced Medical Solutions Group plc
Citigroup Inc.
Deutsche Bank Aktiengesellschaft